Denali Therapeutics (DNLI) vs Enliven Therapeutics (ELVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 100.0% versus a gain of 19.3%. Over five years, ELVN leads with a +177.5% price change compared with -59.0% for DNLI. Denali Therapeutics is the larger company by market cap ($2.98 billion vs $2.98 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | ELVN |
|---|---|---|
| Share price | $18.67 | $40.63 |
| Market cap | $2.98B | $2.98B |
| 1-day change | -2.56% | -1.76% |
| YTD return | +13.08% | +163.83% |
| 1-year return | +19.30% | +99.95% |
| 5-year return | -59.02% | +177.53% |
| EPS (TTM) | $-2.84 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-512.54M | $-103.69M |
| 52-week high | $27.30 | $62.32 |
| 52-week low | $13.75 | $14.79 |
| Distance from 52-week high | -31.61% | -34.80% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.14% | +81.32% |
| Average volume | 1.62M | 1.12M |
| Shares outstanding | 159.85M | 73.27M |
| Employees | 503 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed DNLI by 80.7 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
DNLI vs ELVN FAQ
Which is bigger, Denali Therapeutics or Enliven Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.98B compared with $2.98B for Enliven Therapeutics (ELVN).
Which stock has performed better over the past year, DNLI or ELVN?
ELVN returned +99.95% over the past 12 months, compared with +19.30% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Enliven Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for Enliven Therapeutics.